190 related articles for article (PubMed ID: 33291976)
1. Is there a role for immune checkpoint inhibitors in selected rare subtypes of soft tissue sarcoma?
Assi T; Cesne AL; Mir O
Immunotherapy; 2021 Feb; 13(2):91-93. PubMed ID: 33291976
[No Abstract] [Full Text] [Related]
2. PD-1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma.
Scheinberg T; Lomax A; Tattersall M; Thomas D; McCowage G; Sullivan M; Karim R; Luk PP; Mahar A; Bonar F; Bhadri VA
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1327. PubMed ID: 33314769
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
Tawbi HA; Burgess M; Bolejack V; Van Tine BA; Schuetze SM; Hu J; D'Angelo S; Attia S; Riedel RF; Priebat DA; Movva S; Davis LE; Okuno SH; Reed DR; Crowley J; Butterfield LH; Salazar R; Rodriguez-Canales J; Lazar AJ; Wistuba II; Baker LH; Maki RG; Reinke D; Patel S
Lancet Oncol; 2017 Nov; 18(11):1493-1501. PubMed ID: 28988646
[TBL] [Abstract][Full Text] [Related]
4. The challenge of checkpoint inhibitors in prostate cancer: drugs for the many but useful to a few.
F Slovin S
Immunotherapy; 2020 Mar; 12(4):219-221. PubMed ID: 32172641
[No Abstract] [Full Text] [Related]
5. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.
Starzer AM; Berghoff AS; Hamacher R; Tomasich E; Feldmann K; Hatziioannou T; Traint S; Lamm W; Noebauer-Huhmann IM; Furtner J; Müllauer L; Amann G; Bauer S; Schildhaus HU; Preusser M; Heller G; Brodowicz T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762319
[TBL] [Abstract][Full Text] [Related]
6. Soft tissue sarcomas: are all soft tissue sarcomas treated with the same drugs?
Blay JY; Cassier PA; Ray-Coquard I
Eur J Cancer; 2011 Sep; 47 Suppl 3():S385-8. PubMed ID: 21944026
[No Abstract] [Full Text] [Related]
7. Immunotherapy and Biomarkers in Sarcoma.
Dajsakdipon T; Siripoon T; Ngamphaiboon N; Ativitavas T; Dejthevaporn T
Curr Treat Options Oncol; 2022 Mar; 23(3):415-438. PubMed ID: 35262852
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis.
Saerens M; Brusselaers N; Rottey S; Decruyenaere A; Creytens D; Lapeire L
Eur J Cancer; 2021 Jul; 152():165-182. PubMed ID: 34107450
[TBL] [Abstract][Full Text] [Related]
9. B cells are associated with survival and immunotherapy response in sarcoma.
Petitprez F; de Reyniès A; Keung EZ; Chen TW; Sun CM; Calderaro J; Jeng YM; Hsiao LP; Lacroix L; Bougoüin A; Moreira M; Lacroix G; Natario I; Adam J; Lucchesi C; Laizet YH; Toulmonde M; Burgess MA; Bolejack V; Reinke D; Wani KM; Wang WL; Lazar AJ; Roland CL; Wargo JA; Italiano A; Sautès-Fridman C; Tawbi HA; Fridman WH
Nature; 2020 Jan; 577(7791):556-560. PubMed ID: 31942077
[TBL] [Abstract][Full Text] [Related]
10. Sarcomas: Immune biomarker expression and checkpoint inhibitor trials.
Zhu MMT; Shenasa E; Nielsen TO
Cancer Treat Rev; 2020 Dec; 91():102115. PubMed ID: 33130422
[TBL] [Abstract][Full Text] [Related]
11. Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers.
Colen RR; Rolfo C; Ak M; Ayoub M; Ahmed S; Elshafeey N; Mamindla P; Zinn PO; Ng C; Vikram R; Bakas S; Peterson CB; Rodon Ahnert J; Subbiah V; Karp DD; Stephen B; Hajjar J; Naing A
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849924
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
Miwa S; Yamamoto N; Hayashi K; Takeuchi A; Igarashi K; Tsuchiya H
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621224
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab: a new standard of care in metastatic colorectal cancer.
Saleh K; Kordahi M; Felefly T; Khalife N
Immunotherapy; 2021 Oct; 13(15):1245-1247. PubMed ID: 34542319
[No Abstract] [Full Text] [Related]
14. PD-1 blockade for disseminated Kaposi sarcoma in a patient with atopic dermatitis and chronic CD8 lymphopenia.
Gambichler T; Susok L
Immunotherapy; 2020 May; 12(7):451-457. PubMed ID: 32316815
[TBL] [Abstract][Full Text] [Related]
15. Maintenance avelumab in metastatic bladder cancer as a step towards sequencing immunotherapy.
Samaha H; Samaha R; Sarkis J; Kattan J
Immunotherapy; 2021 Mar; 13(4):271-275. PubMed ID: 33397137
[No Abstract] [Full Text] [Related]
16. Trabectedin and immune checkpoint inhibitors: a blissful combination or another failure in soft tissue sarcomas?
Assi T; Cesne AL
Immunotherapy; 2023 Jan; 15(1):5-8. PubMed ID: 36628569
[No Abstract] [Full Text] [Related]
17. A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032).
Saif A; Verbus EA; Sarvestani AL; Teke ME; Lambdin J; Hernandez JM; Kirsch DG
Ann Surg Oncol; 2023 Feb; 30(2):683-685. PubMed ID: 36396869
[No Abstract] [Full Text] [Related]
18. Current status of immunotherapy for advanced gastric cancer.
Kawazoe A; Shitara K; Boku N; Yoshikawa T; Terashima M
Jpn J Clin Oncol; 2021 Jan; 51(1):20-27. PubMed ID: 33241322
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibition in sarcomas: time to be histology-specific?
Napolitano A; Huang PH; Jones RL; Tu C
Lancet Oncol; 2022 Sep; 23(9):1111-1112. PubMed ID: 36055298
[No Abstract] [Full Text] [Related]
20. Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.
Keung EZ; Burgess M; Salazar R; Parra ER; Rodrigues-Canales J; Bolejack V; Van Tine BA; Schuetze SM; Attia S; Riedel RF; Hu J; Okuno SH; Priebat DA; Movva S; Davis LE; Reed DR; Reuben A; Roland CL; Reinke D; Lazar AJ; Wang WL; Wargo JA; Tawbi HA
Clin Cancer Res; 2020 Mar; 26(6):1258-1266. PubMed ID: 31900276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
